Neutralizing recombinant human antibodies to a conformational V2- and CD4-binding site-sensitive epitope of HIV-1 gp120 isolated by using an epitope-masking procedure.

As part of the goal of assembling a mixture of neutralizing human mAbs for possible prophylaxis and therapy of HIV-1 disease, we describe a strategy by which neutralizing human Abs to a weakly immunogenic epitope can be accessed. From a phage display library derived from an asymptomatic HIV-1 seropositive donor, a panel of recombinant Fabs against the CD4 binding site (CD4bs) of gp120 was retrieved by affinity selection using recombinant gp120 (strain LAI). Two Fabs corresponding to the dominant clones were used to mask the CD4bs epitope(s) before repeating the selection procedure. Four Fabs were then retrieved that had novel heavy chain sequences. Three recognized a novel epitope distinct from that recognized by conventional CD4bs Abs and were defined by the following criteria: 1) second V region (V2 region) dependence indicated by sensitivity to amino acid changes in the V2 loop and by competition with murine anti-V2 mAbs; 2) CD4bs dependence indicated by sensitivity to amino acid changes usually associated with CD4 binding and by inhibition of Fab binding to gp120 by soluble CD4; this dependence seemed to arise via conformational changes rather than by direct binding, as CD4bs Abs enhanced binding of two of the novel Fabs and, in a reversal of the competition format, the novel Fabs did not inhibit soluble CD4 binding to gp120; and 3) equivalent binding to glycosylated and deglycosylated gp120 and significant, although much reduced, binding to denatured gp120 in contrast with CD4bs Abs, which do not bind to deglycosylated or denatured gp120. One of the novel Fabs efficiently neutralized the MN and LAI strains of HIV-1. These results indicate the presence of a novel neutralizing conformational epitope on gp120 sensitive to the V2 loop and the CD4bs and further highlight the conformational flexibility of gp120. The strategy of masking highly immunogenic epitopes with Abs to rescue a broader range of specific Abs from combinatorial libraries should be widely applicable.

[1]  D. Burton,et al.  Recombinant human antibodies: linkage of an Fab fragment from a combinatorial library to an Fc fragment for expression in mammalian cell culture. , 1993, Human antibodies and hybridomas.

[2]  J. Sodroski,et al.  Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies , 1994, Journal of virology.

[3]  J. Morris,et al.  Alteration of HIV-1 infectivity and neutralization by a single amino acid replacement in the V3 loop domain. , 1991, AIDS research and human retroviruses.

[4]  J. Coffin Genetic variation in AIDS viruses , 1986, Cell.

[5]  D R Burton,et al.  Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1 , 1994, Journal of virology.

[6]  J. Goudsmit,et al.  Neutralization of HIV‐1: a paradox of humoral proportions , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  S. Lamers,et al.  Independent variation and positive selection in env V1 and V2 domains within maternal-infant strains of human immunodeficiency virus type 1 in vivo , 1993, Journal of virology.

[8]  C. Barbas,et al.  Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[9]  J. Sodroski,et al.  Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody , 1991, Journal of virology.

[10]  C. Hanson,et al.  Evaluation of monoclonal antibodies to HIV-1 by neutralization and serological assays: an international collaboration. Collaborating Investigators. , 1991, AIDS.

[11]  J. Sodroski,et al.  Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein , 1991, Journal of virology.

[12]  G K Lewis,et al.  Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop , 1993, Journal of virology.

[13]  N. Sullivan,et al.  Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120 , 1993, Journal of virology.

[14]  J. Sodroski,et al.  Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions , 1993, Journal of virology.

[15]  Hans Wolf,et al.  Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS , 1986, Cell.

[16]  Michael Emerman,et al.  Single amino-acid changes in HIV envelope affect viral tropism and receptor binding , 1989, Nature.

[17]  T. White,et al.  The origin of HIV-1 isolate HTLV-IIIB , 1993, Nature.

[18]  Dennis R. Burton,et al.  MONOCLONAL ANTIBODIES FROM COMBINATORIAL LIBRARIES , 1993 .

[19]  J. Davide,et al.  Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. , 1990, Science.

[20]  T. Clackson,et al.  Making antibody fragments using phage display libraries , 1991, Nature.

[21]  D. Burton,et al.  Generation of diverse high-affinity human monoclonal antibodies by repertoire cloning. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[22]  D R Burton,et al.  A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[23]  C. Barbas,et al.  Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[24]  K. Steimer,et al.  Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies. , 1990, AIDS research and human retroviruses.

[25]  D. Altschuh,et al.  Determination of kinetic constants for the interaction between a monoclonal antibody and peptides using surface plasmon resonance. , 1992, Biochemistry.

[26]  J. Sodroski,et al.  Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody , 1993, Journal of virology.

[27]  E. Freed,et al.  Identification of the principal neutralizing determinant of human immunodeficiency virus type 1 as a fusion domain , 1991, Journal of virology.

[28]  L. Montagnier,et al.  Influence of carbohydrate moieties on the immunogenicity of human immunodeficiency virus type 1 recombinant gp160 , 1992, Journal of virology.

[29]  S. Olofsson,et al.  Activity of herpes simplex virus type 1-specified glycoprotein C antigenic site II epitopes reversibly modulated by peripheral fucose or galactose units of glycoprotein oligosaccharides. , 1990, The Journal of general virology.

[30]  J. Moore,et al.  The role of the V3 loop of gp120 in HIV infection. , 1991, AIDS.

[31]  K. Steimer,et al.  Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons , 1992, Journal of virology.

[32]  J. Ledbetter,et al.  Functional roles of the V3 hypervariable region of HIV-1 gp160 in the processing of gp160 and in the formation of syncytia in CD4+ cells. , 1992, Virology.

[33]  D. Ho,et al.  Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Role of N-linked glycans in the interaction between the envelope glycoprotein of human immunodeficiency virus and its CD4 cellular receptor: structural enzymatic analysis. , 1990, Disease markers.

[35]  H. Sheppard,et al.  Application of a rapid microplaque assay for determination of human immunodeficiency virus neutralizing antibody titers , 1990, Journal of clinical microbiology.

[36]  H. Schuitemaker,et al.  Relation of phenotype evolution of HIV-1 to envelope V2 configuration. , 1993, Science.

[37]  G. Nakamura,et al.  Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor , 1987, Cell.

[38]  C. Barbas,et al.  Combinatorial immunoglobulin libraries on the surface of phage (Phabs): Rapid selection of antigen-specific fabs , 1991 .

[39]  J. Moore,et al.  Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans , 1993, Journal of virology.

[40]  J. Groopman,et al.  Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients. , 1985, Science.

[41]  J. Sodroski,et al.  Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region , 1992, Journal of virology.

[42]  S. Wain-Hobson,et al.  Complex intrapatient sequence variation in the V1 and V2 hypervariable regions of the HIV-1 gp 120 envelope sequence. , 1992, Virology.

[43]  S. Yoshitake,et al.  Enzyme-labeling of antibodies and their fragments for enzyme immunoassay and immunohistochemical staining. , 1983, Journal of immunoassay.

[44]  R. Karlsson,et al.  Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. , 1991, Journal of immunological methods.

[45]  Q. Sattentau,et al.  Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding , 1991, The Journal of experimental medicine.

[46]  M. Hammarskjöld,et al.  Mutations in the principal neutralization determinant of human immunodeficiency virus type 1 affect syncytium formation, virus infectivity, growth kinetics, and neutralization , 1992, Journal of virology.

[47]  J. Moore The reactivities of HIV-1+ human sera with solid-phase V3 loop peptides can be poor predictors of their reactivities with V3 loops on native gp120 molecules. , 1993, AIDS research and human retroviruses.

[48]  C. Barbas,et al.  Selection of human anti-hapten antibodies from semisynthetic libraries. , 1993, Gene.

[49]  G R Pilkington,et al.  Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries. , 1993, Journal of molecular biology.

[50]  Q. Sattentau,et al.  Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains , 1993, Journal of virology.

[51]  D R Burton,et al.  Human monoclonal antibodies against a plethora of viral pathogens from single combinatorial libraries. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[52]  Robert A. Bloodgood,et al.  Detection of monoclonal antibodies specific for carbohydrate epitopes using periodate oxidation. , 1985, Journal of immunological methods.

[53]  Q. Sattentau,et al.  Novel anti-CD4 monoclonal antibodies separate human immunodeficiency virus infection and fusion of CD4+ cells from virus binding , 1990, The Journal of experimental medicine.

[54]  J. Sodroski,et al.  Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type 1 gp120 glycoprotein conferred by a gp41 amino acid change , 1994, Journal of virology.

[55]  D. Ho,et al.  Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120 , 1992, Journal of virology.

[56]  H. Lyerly,et al.  Interaction between the human T-cell lymphotropic virus type IIIB envelope glycoprotein gp120 and the surface antigen CD4: role of carbohydrate in binding and cell fusion. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[57]  J. Sodroski,et al.  Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding , 1990, Journal of virology.

[58]  A J Langlois,et al.  Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[59]  Reed J. Harris,et al.  Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. , 1990, The Journal of biological chemistry.